Autoimmune gene expression profiling of fingerstick whole blood in Chronic Fatigue Syndrome.
Wang, Zheng, Waldman, Michelle F, Basavanhally, Tara J et al. · Journal of translational medicine · 2022 · DOI
Quick Summary
Researchers tested blood samples from 166 ME/CFS patients and 83 healthy people to look for immune system clues that might explain the disease. They found that six specific genes related to immune function were more active in patients with severe, bedridden ME/CFS compared to those with milder disease. The study suggests these genes could potentially be used as biomarkers to identify how severe someone's ME/CFS is and might point toward new treatments.
Why It Matters
This study provides potential biological markers that could help clinicians differentiate disease severity in ME/CFS—a condition currently lacking any diagnostic test. The identification of immune genes similar to those dysregulated in other autoimmune diseases opens new avenues for understanding ME/CFS pathophysiology and developing targeted treatments.
Observed Findings
49% of ME/CFS participants reported being house-bound or bedridden with severe symptoms.
Six genes (IKZF2, IKZF3, HSPA8, BACH2, ABCE1, CD3D) showed significantly higher expression in severe/bedridden ME/CFS patients versus mild-to-moderate patients.
These six genes were further upregulated in the 22 bedridden participants with both ME/CFS and other autoimmune diseases.
Viral detection was rare: only 9 positive samples out of 240 tested (1 EBV, 8 HHV6), suggesting low active viral involvement in this cohort.
Three of the identified genes (IKZF3, IKZF2, BACH2) are implicated in systemic lupus erythematosus and rheumatoid arthritis.
Inferred Conclusions
Gene expression biomarkers can differentiate ME/CFS patients by disease severity level.
These genes represent potential therapeutic targets for developing new ME/CFS treatments.
ME/CFS may share immune dysfunction mechanisms with other autoimmune diseases, particularly in severe cases.
Home-based, app-mediated patient recruitment and sample collection is a feasible approach for ME/CFS research.
Remaining Questions
Do these gene expression patterns predict disease progression or response to treatment in longitudinal follow-up?
What This Study Does Not Prove
This study does not establish that these gene expression patterns cause ME/CFS severity; it only shows association. The study cannot determine whether gene upregulation is a cause, consequence, or marker of disease. The small number of viral positives does not rule out viral triggers in other patient subgroups, and findings require validation in larger, prospective studies before clinical application.
What is the functional significance of these specific genes in ME/CFS pathophysiology, and do they have causal roles?
Can these biomarkers be validated in larger, diverse populations, and what is their sensitivity and specificity for disease diagnosis or severity assessment?
What role do viral reactivation and immune dysregulation play in ME/CFS subsets, and why was viral detection so low in this cohort?